In a comparative study of middle-aged patients with multiple sclerosis (MS) on rituximab (Rituxan; Genentech) and ocrelizumab (Ocrevus; Genentech), findings showed similar safety and efficacy over a 2-year period.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045